Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The evidence that motivated an independent review of breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

    Research output: Contribution to journalJournal articleResearchpeer-review

  • ABCTB Investigators
View graph of relations

Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.

Original languageEnglish
JournalCurrent Medical Literature. Breast Cancer
Volume5
Pages (from-to)38
ISSN2374-4677
DOIs
Publication statusPublished - 2019

ID: 58983776